Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegvaliase OLE (>40 mg/day) in Adults with PKU
NCT03694353Phase 3Completed
- Sponsor
- BioMarin Pharmaceutical
- Start
- Sep 2018
- Primary completion
- Jan 2021
- Modality
- PEGylated Peptides, Replacement Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pegvaliase in phenylketonuria (PKU), sponsored by BioMarin Pharmaceutical. Primary endpoints: Number of Participants With Treatment-emergent Adverse Events at Day 741 and Change in Blood Phe Concentration at Week 121. Started Sep 2018; status: completed.
02
Drugs
pegvaliase
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on NCT03694353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03694353.